Establish Targeted Radiopharmaceuticals as the Next Pillar of Oncology Drugs Through Innovating Novel Design Approaches, Showcasing Emerging Clinical Data, & Streamlining Isotope Supply & Distribution
Radioligand therapy is evolving rapidly. With new targets like HER2 and FAP coming into focus, and promising data emerging beyond PSMA and SSTR2, there’s real momentum building in the field. But to fully unlock the potential of these therapies across Europe, and to integrate RLT as the next pillar of oncology treatment, we need more than scientific innovation.
We need the right infrastructure and global harmonisation to match the innovation – from reliable isotope supply and scalable manufacturing, to clearer regulatory pathways, streamlined clinical development, and healthcare systems ready to deliver these therapies safely and effectively. Crossing those hurdles is what will turn potential into real impact for patients.
That’s where the 7th Targeted Radiopharmaceuticals Summit Europe comes in. This is the meeting for anyone passionate about bringing the next wave of TRPs to patients. Whether you’re working in discovery, clinical development, manufacturing, or regulation, you’ll find practical insights, open conversations, and solutions you can act on. Together, we can build the path that takes RLTs from promise to practice.
Attending Companies Include







